title: [Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer].
abstract: The effects of PSK in combination with Mitomycin C, Adriamycin and Tegafur were studied in 168 patients who underwent gastrectomy for gastric cancer. The study group receiving PSK showed improved survival and there was a significant difference in the estimated survival. An improved survival rate was also shown at stages III and IV, in the group given an FAM regimen and in the group with well differentiated adenocarcinoma.
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011182:Postoperative Care; D011379:Prognosis; D011509:Proteoglycans / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D011509:Proteoglycans; D005641:Tegafur; C010770:polysaccharide-K; D016685:Mitomycin; D004317:Doxorubicin